Increased non-HDL-C and waist circumference significant predictors of Metabolic syndrome

The key results of the study are:

• A total of 1599 subjects developed MetS, while 3085 did not.
• There was an association between Non-HDL-C levels ≥ 130 and a 42% higher risk of developing MetS (RR: 1.42).
• Considering MetS components, elevated WC had the strongest association with MetS incidence (RR, 2.32), whereas triglyceride (TG) levels ≥ 150 mg/dL had the weakest association (RR, 1.23).
• Higher HDL-C levels were 20% protective against the risk of MetS (RR, 0.8).
• There was no significant link between fasting blood glucose (FBG) levels ≥ 100 mg/dL and MetS burden.
• Systolic BP levels ≥ 130 mmHg or diastolic BP levels ≥ 85 mmHg increased the risk of MetS incidence (RR, 1.25)

To mitigate the risk of MetS development, strategies targeting non-HDL-C levels and weight loss should be emphasized.

Elevated WC increases the risk of metabolic disorders by 2.3-fold, they noted. Weight loss strategies, specifically abdominal fat management, can benefit subjects susceptible to MetS development.

Our study addressed the research gap regarding the association of non-HDL-C with the incidence of MetS and its components over a long follow-up period, they said. As acknowledged, the study was supported by Mashhad University of Medical Sciences.

Reference:

Vazirian, Fatemeh, et al. "Non-HDL Cholesterol and Long-term Follow-up Outcomes in Patients With Metabolic Syndrome." Lipids in Health and Disease, vol. 22, no. 1, 2023, p. 165.